Chemed's stock experienced a significant intraday plummet of 15.96% on Thursday, driven by a combination of disappointing financial results and a negative analyst action.

The sharp decline followed the company's report of declining fourth-quarter earnings that fell short of analyst forecasts. Furthermore, Chemed's 2026 adjusted earnings per share guidance also missed market expectations, signaling potential challenges ahead for the healthcare services provider.

Adding to the negative sentiment, Jefferies cut its price target for Chemed from $475 to $400. Analyst target price reductions often reflect concerns about a company's future valuation and growth prospects, prompting investors to reassess their positions.